**Angiochem to Present Data on its Lead Oncology Compounds at the 2013 San Antonio Breast Cancer Symposium**

*Clinical Data on ANG1005 a Peptide-drug Conjugate in Patients with Brain Metastases from Breast Cancer and Preclinical Data on ANG4043 an Anti-HER2 Monoclonal Antibody in Animal Models with Intracranial Breast Tumor Cells*

Montreal, Canada – December xx, 2013 – Angiochem, a clinical stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB), today announced that its lead oncology compound, ANG1005, a novel paclitaxel-peptide drug conjugate in development for breast cancer patients with brain metastasis and patients with primary brain cancer, and ANG4043, a peptide-antibody conjugate of anti-HER2 in development for neuro-oncology indications, have been selected for presentation at the 2013 San Antonio Breast Cancer Symposium being held December 10-14, 2013 at the Henry B. Gonzalez Convention Center in San Antonio, Texas.

**Poster Presentations:**

(Abstract/Poster # P4-01-09): Friday December 13, 7:30-9:00 am, “**F-FLT-PET/CT for the Prediction of Response to ANG-1005 Therapy in Patients with Brain Metastases from Breast Cancer**,” Laleh Amiri-Kordestani, MD, National Cancer Institute, Center for Cancer Research, in a poster session on Detection and Diagnosis: Molecular, Functional, and Novel Imaging, Exhibit Halls A & B.

(Abstract/Poster # P6-11-05), Saturday, December 14, 7:30-9:00 am, “ANG4043, a brain-penetrant anti-HER2 mAb increases survival of mice bearing intracranial BT-474 breast tumor cells, ”Jean E. Lachowicz, Ph.D., Angiochem Inc., in a poster session on Treatment for Brain Metastases, Exhibit Hall C.

**About ANG1005**

ANG1005 is a novel paclitaxel-peptide drug conjugate that represents the first oncology product to leverage the (LRP-1) pathway to cross the blood-brain barrier (BBB) and enter cancer cells. ANG1005 has been studied in over 200 patients in three clinical studies; two phase 1 studies where the product has shown tolerability similar to paclitaxel and indications of activity, and a Phase 2 study for which the intent-to-treat (ITT) analysis demonstrated encouraging signs of anti-tumor activity and was reported at the 2013 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference. A multi-study Phase 2 clinical program has been initiated to further confirm the clinical activity of ANG1005 observed in these earlier studies.

[**About Angiochem**](http://www.angiochem.com/en/profile.shtml)

Angiochem is a clinical-stage biotechnology company discovering and developing new breakthrough peptide drug conjugates that leverage the LRP-1 mediated pathway to cross the BBB to treat neurological diseases. These new compounds have the potential to address significant medical needs, many of which are insurmountable due to the fundamental physiological challenge posed by the BBB.

Angiochem is developing a focused product pipeline, including small molecules and biologics, for the potential treatment of a wide range of CNS diseases, including primary brain cancer, brain metastases, lysosomal storage diseases and pain. Founded in 2003, Angiochem maintains headquarters in Montreal, Canada. For additional information about the Company, please visit [http://www.angiochem.com](http://www.angiochem.com/).

# # #

Media Contact:

Gina Nugent

The Yates Network

617-460-3579

Business Development Contact:

Catherine Gagnon

Angiochem, Inc.

514-788-7800 x204